Dr. Han is a leader in biopharmaceutical development with over 20 years of experience in multiple therapeutic areas in biotechnology and pharmaceutical industry. Dr. Han is responsible for nonclinical safety, pharmacokinetics, and bioanalysis at Tallac Therapeutics. Prior to Tallac Therapeutics, she recently held various leadership positions at ProLynx, ALX Oncology, and Pfizer in drug safety, translational medicine, and operations. Dr. Han received her Ph.D. in Pharmacology and Toxicology from University of California, Irvine and is a Board Certified Toxicologist.